205 related articles for article (PubMed ID: 26721189)
1. Patent production is a prerequisite for successful exit of a biopharmaceutical company.
Saotome C; Nakaya Y; Abe S
Drug Discov Today; 2016 Mar; 21(3):406-9. PubMed ID: 26721189
[TBL] [Abstract][Full Text] [Related]
2. Patent holdings of US biotherapeutic companies in major markets.
Sebastian TE; Yerram CB; Saberwal G
Drug Discov Today; 2009 May; 14(9-10):442-5. PubMed ID: 19429502
[TBL] [Abstract][Full Text] [Related]
3. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
Sahoo N; Manchikanti P
BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
[TBL] [Abstract][Full Text] [Related]
4. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
Pillai X; Kinney WA
Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
[TBL] [Abstract][Full Text] [Related]
5. With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS.
Angeli F
Health Policy Plan; 2014 May; 29(3):280-91. PubMed ID: 23558959
[TBL] [Abstract][Full Text] [Related]
6. How many patents does a biopharmaceutical company need?
Parida DK; Mehdiratta R; Saberwal G
Nat Biotechnol; 2008 Jul; 26(7):763-6. PubMed ID: 18612295
[TBL] [Abstract][Full Text] [Related]
7. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
[TBL] [Abstract][Full Text] [Related]
8. Strange Bedfellows: Native American Tribes, Big Pharma, and the Legitimacy of Their Alliance.
Kennedy DC
Duke Law J; 2019 Apr; 68(7):1433-68. PubMed ID: 30995705
[TBL] [Abstract][Full Text] [Related]
9. Patent indicators: a window to pharmaceutical market success.
Guo Y; Hu Y; Zheng M; Wang Y
Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
[TBL] [Abstract][Full Text] [Related]
10. Can regenerative medicine save Big Pharma’s business model from the patent cliff?
Denoon A; Vollebregt E
Regen Med; 2010 Sep; 5(5):687-90. PubMed ID: 20868323
[No Abstract] [Full Text] [Related]
11. First-to-patent does not predict first- or best-in-class: analysis of approved small molecule vs. biologic drugs.
Roland GE; Xu JJ; Wagner JA
Clin Pharmacol Ther; 2015 Jan; 97(1):19-21. PubMed ID: 25670379
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
Jones TM
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-58. PubMed ID: 20213918
[No Abstract] [Full Text] [Related]
13. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
[TBL] [Abstract][Full Text] [Related]
14. Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act.
Genieser LH; McCann CE
Pharm Pat Anal; 2012 Sep; 1(4):415-26. PubMed ID: 24236880
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
16. The transatlantic divide: how divisional and continuing patent application filing practice differs between the USA and Europe.
Nytko-Lutz E; Crease D
Pharm Pat Anal; 2012 Jul; 1(3):245-8. PubMed ID: 24236836
[TBL] [Abstract][Full Text] [Related]
17. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
18. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
Cockburn I; Long G
Expert Opin Ther Pat; 2015 Jul; 25(7):739-42. PubMed ID: 25927945
[TBL] [Abstract][Full Text] [Related]
19. Strategic options for brand-name prescription drugs when patents expire.
Mehta SC; Mehta SS
Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
[TBL] [Abstract][Full Text] [Related]
20. Canada ordered to implement WTO ruling against "stockpiling" of generic drugs.
Elliott R
Can HIV AIDS Policy Law Rev; 2000; 5(4):27. PubMed ID: 11833161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
